Key highlights
- 1The pulsed field ablation market is expected to reach USD 24 billion by 2036, at a CAGR of 19.0% from 2026 to 2036, driven by atrial fibrillation prevalence, safety, and rapid adoption.
- 2Adoption is already widespread. Pulsed field ablation was used in about 49% of first atrial fibrillation ablation procedures by mid-2025, according to a European Heart Rhythm Association survey, with adoption still rolling out as about 23% of centers had not yet started.
- 3Safety is the key advantage. Pulsed field ablation is tissue-selective and non-thermal, largely sparing the esophagus, phrenic nerve and surrounding structures, reducing the serious complications associated with thermal ablation.
- 4Faster procedures drive uptake. Procedure time efficiency was cited by about 60% of adopters as the primary driver, and pulsed field ablation reduces procedure times by about 30% to 50%.
- 5Multiple approved systems compete. The FDA approved pulsed field ablation systems from several manufacturers, including Boston Scientific's FARAPULSE, Medtronic's PulseSelect and Sphere-360, Johnson & Johnson MedTech's VARIPULSE, and Abbott's Volt.
- 6Competition is intensifying. Four major device companies now offer pulsed field ablation, with single-shot and focal catheters and mapping integration, accelerating adoption and innovation.
- 7Key companies include Boston Scientific Corporation, Medtronic plc, Johnson & Johnson MedTech (Biosense Webster), Abbott Laboratories, and emerging innovators.
Report Overview
The pulsed field ablation market covers the generators, catheters and mapping integration used for non-thermal electroporation ablation of cardiac arrhythmias, primarily atrial fibrillation, spanning single-shot and focal catheters, paroxysmal and persistent atrial fibrillation and other arrhythmias, and hospital and cardiac-center settings. Thermal radiofrequency and cryoablation, and non-cardiac ablation, are outside the scope except for comparison. Pulsed field ablation is the emerging, safety-differentiated ablation modality rapidly displacing thermal ablation. Demand is shaped by atrial fibrillation prevalence, safety, procedure efficiency, and competition among approved systems. This report examines the size, drivers, catheter types, indications, components, pricing, regions, competition, recent developments, and outlook of the market, and provides recommendations. Sizing is built bottom-up from systems and catheters by type, indication and region, and reflects pulsed field ablation used in cardiac arrhythmia treatment.
Market dynamics
Drivers
- 01Atrial fibrillation prevalence is the primary driver as atrial fibrillation is the most common sustained arrhythmia and its prevalence rises with an aging population, increasing the number of ablation procedures.
- 02The safety of tissue-selective ablation is a strong driver as pulsed field ablation is non-thermal and largely spares the esophagus, phrenic nerve and other structures, reducing the serious complications of thermal ablation and giving physicians confidence to treat more patients.
- 03Faster procedure times are a driver as pulsed field ablation reduces procedure times by about 30% to 50%, cited by most adopters as the primary reason, improving throughput and cost-efficiency.
- 04Rapid adoption following approvals is a driver as the FDA and other regulators approved systems from several manufacturers, and physician uptake has been fast.
Opportunities
- 01Persistent atrial fibrillation and ablation beyond pulmonary vein isolation are a leading opportunity, as pulsed field ablation extends to more complex cases and additional lesion sets.
- 02Focal and mapping-integrated systems are an opportunity as point-by-point and mapping-integrated catheters, such as those combining pulsed field ablation with electroanatomical mapping, address complex arrhythmias.
- 03The shift to outpatient and ambulatory settings is an opportunity as faster, safer procedures enable more procedures outside the hospital.
- 04Emerging markets are an opportunity as adoption spreads globally.
Trends
- 01Rapid adoption is the defining trend as pulsed field ablation reached about half of first atrial fibrillation ablations by mid-2025 and continues to displace thermal ablation.
- 02Multi-vendor competition is a structural trend as four major device companies now offer approved systems, accelerating innovation and adoption.
- 03Mapping integration is a technology trend as manufacturers integrate pulsed field ablation with electroanatomical mapping for complex cases, as in the Affera and Varipulse platforms.
- 04Single-shot dominance is a format trend as single-shot catheters that isolate the pulmonary veins in few applications lead adoption, with focal catheters growing for complex cases.
Report Summary
| Base Year | 2025 |
|---|---|
| Forecast Period | 2026-2036 |
| Market Size (2025) | USD 3.5 billion |
| Market Size (2026) | USD 4.2 billion |
| Market Size (2036) | USD 24 billion |
| CAGR (Value) | 19.0% (2026-2036) |
| Format | PDF & Excel |
| Segments Covered | By Catheter Type: Single-Shot, Focal / Point-by-Point. By Indication: Paroxysmal AF, Persistent AF, Other Arrhythmias. By Component; By Region. |
| Geographies Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
| Key Companies | Boston Scientific Corporation, Medtronic plc, Johnson & Johnson MedTech (Biosense Webster), Abbott Laboratories, CardioFocus, Kardium, Adagio Medical, Field Medical, Pulse Biosciences, Other Companies |
Segmental analysis
By Catheter Type
- Single-shot catheters hold the largest share at about 70% of the market in 2026, with focal or point-by-point catheters accounting for the remainder.
- Single-shot catheters which isolate the pulmonary veins in a small number of applications using basket, flower, loop or spherical designs, are the largest type because pulmonary vein isolation is the core of atrial fibrillation ablation and single-shot catheters deliver it quickly and safely, and the leading systems are single-shot.
- Focal or point-by-point catheters which ablate lesion by lesion, often integrated with mapping, are a growing type for persistent atrial fibrillation and complex arrhythmias requiring additional lesions.
The dominance of single-shot catheters reflects the centrality of pulmonary vein isolation, while focal catheters grow for complex cases.
By Indication
- Paroxysmal atrial fibrillation holds the largest share at about 60% of the market in 2026, with the remaining share divided across persistent atrial fibrillation and other arrhythmias.
- Paroxysmal atrial fibrillation is the largest indication because it is the most common target for ablation and is well addressed by pulmonary vein isolation, where pulsed field ablation is established.
- Persistent atrial fibrillation is a growing indication as pulsed field ablation extends to more complex cases requiring additional lesion sets.
- Other arrhythmias including atrial flutter and ventricular arrhythmias, are an emerging indication as the technology broadens.
The dominance of paroxysmal atrial fibrillation reflects its prevalence and suitability for pulmonary vein isolation.
By Component
- Catheters the single-use disposables that deliver the ablation, hold the largest share, at about 70% of the market in 2026, as they are consumed in every procedure and generate recurring revenue.
- Generators the capital equipment that delivers the pulsed field energy, are a smaller share but essential, and are placed to drive catheter pull-through.
- Mapping and accessories including electroanatomical mapping integration and supporting devices, complete the segment.
The dominance of catheters reflects their recurring, per-procedure use, and the razor-and-blade model in which generators enable catheter sales.
Geographic analysis
North America Pulsed Field Ablation Market
North America is the largest regional market driven by a large atrial fibrillation patient population, high ablation volumes, early approvals and rapid adoption, and the presence of the leading device companies. The region leads in pulsed field ablation adoption and hosts Boston Scientific, Medtronic, Johnson & Johnson MedTech and Abbott. Strong procedure volumes, reimbursement and adoption make North America the leading market for pulsed field ablation.
Europe Pulsed Field Ablation Market
Europe is a major market with early adoption of pulsed field ablation, high-volume centers and strong uptake, particularly in Western Europe where the European Heart Rhythm Association survey found the highest adoption. European centers were among the first to adopt pulsed field ablation, and the region has significant ablation volumes. Europe is a leading and fast-growing market with early and deep adoption.
Asia-Pacific and Rest of World
Asia-Pacific is a large and fast-growing market with rising atrial fibrillation prevalence, growing ablation volumes, and approvals such as Varipulse in Japan, and adoption spreading across China, Japan and other markets. The rest of the world adds growing demand as pulsed field ablation is approved and adopted. These regions add strong growth as adoption spreads globally from the leading markets.
Pricing Analysis
Pricing in pulsed field ablation reflects the capital generator and the recurring catheter, and is shaped by reimbursement. Systems follow a razor-and-blade model, with generators placed and single-use catheters generating recurring, per-procedure revenue at a premium reflecting the technology and its clinical value. Reimbursement for ablation procedures underpins pricing, and pulsed field ablation's efficiency and safety support its value. Several factors set price. The catheter is the main recurring cost, priced at a premium as a single-use, advanced device. The generator is a capital cost, sometimes placed to drive catheter sales. Reimbursement and health-system budgets shape pricing, as ablation is a reimbursed procedure. Competition affects price, as four major companies compete, which may moderate catheter prices over time. Procedure efficiency supports value, as faster procedures improve center economics. Mapping integration affects system cost.
The trajectory of pricing depends on competition, adoption and reimbursement, and strong adoption supports the market even as competition among the majors influences catheter pricing.
Competitive landscape
The market is led by major cardiac device companies and includes emerging innovators. Boston Scientific leads with its FARAPULSE pulsed field ablation system, an early and widely adopted single-shot system. Medtronic offers PulseSelect, approved by the FDA in December 2023, and the Sphere-360 and Affera mapping-integrated system. Johnson & Johnson MedTech, through Biosense Webster, offers the VARIPULSE system, integrated with its Carto mapping, and the OMNYPULSE focal catheter, with Varipulse approved in markets including Japan. Abbott offers the Volt pulsed field ablation system. Emerging companies including CardioFocus, Kardium, Adagio Medical, Field Medical and Pulse Biosciences develop pulsed field and related ablation technologies.
Competition turns on safety and efficacy data, procedure efficiency, catheter design and mapping integration, and clinical and commercial support, and the market is a fast-growing, competitive field led by four major companies. Atrial fibrillation prevalence, safety and adoption favour companies with proven systems, strong clinical evidence and mapping integration, and Boston Scientific leads while Medtronic, Johnson & Johnson MedTech and Abbott compete strongly, and emerging companies pursue differentiated approaches. The field is highly dynamic, with rapid adoption, new system launches and expanding indications reshaping competition.
Voice of Customer
We adopted pulsed field ablation quickly because it is safer, largely sparing the esophagus and phrenic nerve, which lets us ablate with more confidence, and it is faster, cutting our procedure times substantially. Single-shot pulmonary vein isolation is our workhorse, and we are extending to persistent cases with mapping-integrated systems, so the technology and evidence drive our choice of system.
Electrophysiologist, high-volume center (North America):
Pulsed field ablation has become our default for first atrial fibrillation ablations, and the safety and efficiency improve our throughput and outcomes. We evaluate systems on clinical evidence, catheter design and mapping integration, and with several approved systems we have real choice, though the recurring catheter cost is a consideration for our budget.
Cardiology department head, hospital (Europe):
As pulsed field ablation is approved in our market, we are adopting it for its safety and speed, and demand from our electrophysiologists is strong. We weigh the capital generator and recurring catheter costs against procedure efficiency and reimbursement, and we value suppliers with strong support and training.
Procurement director, cardiac center (Asia-Pacific):
Analyst perspective
The pulsed field ablation market is one of the fastest-growing and most disruptive categories in cardiology, rapidly displacing thermal ablation for atrial fibrillation. The clinical logic is compelling: pulsed field ablation is non-thermal and tissue-selective, largely sparing the esophagus, phrenic nerve and surrounding structures, which addresses the serious complications of radiofrequency and cryoablation, and it is faster, cutting procedure times by about 30% to 50%. Adoption has been extraordinary, reaching about half of first atrial fibrillation ablations by mid-2025, and four major device companies now offer approved systems, from Boston Scientific's market-leading FARAPULSE to Medtronic's, Johnson & Johnson MedTech's and Abbott's systems, intensifying competition and innovation. Rising atrial fibrillation prevalence and the shift toward safer, more efficient ablation underpin strong growth.
The honest considerations are competition and pricing, evidence maturity, and the base effect. The rapid entry of four major competitors, plus emerging innovators, will intensify competition and may pressure catheter pricing over time, so market value growth may lag procedure growth as prices normalise, and market shares are shifting quickly. Long-term efficacy and durability data, and evidence in persistent atrial fibrillation and beyond pulmonary vein isolation, are still maturing, so clinical questions remain even as safety is well established. The market has grown from a small base very fast, so growth rates will moderate as adoption saturates first-line pulmonary vein isolation and expands into more complex and new indications. The market should be assessed on adoption saturation, competitive dynamics and pricing, and expansion into persistent atrial fibrillation and new indications rather than on the adoption story alone, and the safety and efficiency of pulsed field ablation and rising atrial fibrillation prevalence support very strong growth, with competition, pricing and evidence the key variables.
Key Strategic Developments
- December 2023: The FDA approved Medtronic's PulseSelect pulsed field ablation system, one of the first pulsed field ablation approvals, alongside Boston Scientific's FARAPULSE.
- 2024-2025: The FDA approved pulsed field ablation systems from several manufacturers, and Johnson & Johnson MedTech's VARIPULSE and Abbott's Volt entered the market, with Varipulse approved in markets including Japan.
- By mid-2025: A European Heart Rhythm Association survey found pulsed field ablation used in about 49% of first atrial fibrillation ablation procedures, with higher adoption in high-volume and Western European centers.
- 2024-2026: Manufacturers integrated pulsed field ablation with electroanatomical mapping, as in the Affera and Varipulse platforms, and introduced focal catheters such as OMNYPULSE for complex cases.
- 2024-2026: Procedure time efficiency, cited by about 60% of adopters, and safety drove rapid adoption, with pulsed field ablation reducing procedure times by about 30% to 50%.
Strategic Recommendations
For device companies
The priority is to build clinical evidence, expand indications, and integrate mapping while competing on catheter design and support, because the market is adopting rapidly and competition among four majors is intensifying. Companies should generate long-term efficacy and durability data, extend to persistent atrial fibrillation and beyond pulmonary vein isolation, integrate pulsed field ablation with mapping, and support physicians with training, while managing catheter pricing as competition grows. Placing generators to drive catheter pull-through and pursuing emerging markets strengthen the position.
For hospitals and cardiac centers
The recommendation is to adopt pulsed field ablation for its safety and efficiency, selecting systems on evidence, catheter design and mapping integration, and to weigh capital and recurring costs against procedure efficiency and reimbursement. For investors, this is one of the fastest-growing, most competitive categories in cardiology, to evaluate on adoption saturation, competitive dynamics and pricing, and indication expansion rather than on the adoption story alone, recognising that safety, efficiency and atrial fibrillation prevalence support very strong growth while competition, pricing and evidence maturity are the key variables.
Sustainability impact
Patient Safety and Outcomes
Pulsed field ablation reduces the serious complications of thermal ablation, improving patient safety in a common procedure.Pulsed field ablation supports patient safety.
By selectively ablating heart tissue while largely sparing the esophagus, phrenic nerve and surrounding structures, pulsed field ablation reduces the risk of serious complications compared with thermal ablation, improving patient safety and outcomes in atrial fibrillation treatment.
Procedure Efficiency and Health-System Capacity
Faster pulsed field ablation procedures improve throughput and expand access to arrhythmia treatment. Pulsed field ablation supports health-system efficiency.
By reducing procedure times by about 30% to 50%, pulsed field ablation improves the efficiency of ablation, allowing centers to treat more patients and expanding access to arrhythmia treatment, an important health-system contribution.
Access and Health Equity
Wider, safer, more efficient ablation can expand access to effective atrial fibrillation treatment. Pulsed field ablation supports access.
By making ablation safer and more efficient, pulsed field ablation can support broader access to effective atrial fibrillation treatment across regions and settings, though access depends on the cost of systems and on reimbursement.
Single-Use Devices and Waste
The sustainability of pulsed field ablation depends on managing the waste from single-use catheters and devices. Pulsed field ablation requires device stewardship.
By relying on single-use catheters, pulsed field ablation generates medical device waste, so responsible management, and where feasible reprocessing and recycling, of single-use components is part of the sustainability of the procedure.
Table of contents
14 chapters · 220 pages · click to expandFrequently asked questions
The pulsed field ablation market was valued at USD 3.5 billion in 2025 and is projected to reach USD 24 billion by 2036, growing from USD 4.2 billion in 2026, at a CAGR of 19.0% from 2026 to 2036, driven by atrial fibrillation prevalence, safety, and rapid adoption.